Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06309966
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-03-08
Brief Title:
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Sponsor:
Biohaven Therapeutics Ltd
Organization:
Biohaven Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 23 Multicenter Randomization Double-Blind Placebo-Controlled Study to Evaluate the Efficacy Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RISE 3
Brief Summary:
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-808811-21 | REGISTRY | EU CTR | None |